Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Selection of a Ligand-Binding Neutralizing Antibody Assay for Benralizumab: Comparison with an Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Cell-Based Assay.

Wu Y, Akhgar A, Li JJ, Yu B, Chen C, Lee N, White WI, Roskos LK.

AAPS J. 2018 Mar 14;20(3):49. doi: 10.1208/s12248-018-0207-8.

PMID:
29541868
2.

T follicular helper-like cells contribute to skin fibrosis.

Taylor DK, Mittereder N, Kuta E, Delaney T, Burwell T, Dacosta K, Zhao W, Cheng LI, Brown C, Boutrin A, Guo X, White WI, Zhu J, Dong H, Bowen MA, Lin J, Gao C, Yu L, Ramaswamy M, Gaudreau MC, Woods R, Herbst R, Carlesso G.

Sci Transl Med. 2018 Mar 7;10(431). pii: eaaf5307. doi: 10.1126/scitranslmed.aaf5307.

PMID:
29514998
3.

Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.

Guo X, Higgs BW, Bay-Jensen AC, Wu Y, Karsdal MA, Kuziora M, Godwood A, Close D, Ryan PC, Roskos LK, White WI.

Rheumatology (Oxford). 2018 Jan 1;57(1):175-184. doi: 10.1093/rheumatology/kex383.

PMID:
29069507
4.

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.

Weinblatt ME, McInnes IB, Kremer JM, Miranda P, Vencovsky J, Guo X, White WI, Ryan PC, Godwood A, Albulescu M, Close D, Burmester GR.

Arthritis Rheumatol. 2018 Jan;70(1):49-59. doi: 10.1002/art.40323.

5.

Statistical Models for the Analysis of Isobaric Tags Multiplexed Quantitative Proteomics.

D'Angelo G, Chaerkady R, Yu W, Hizal DB, Hess S, Zhao W, Lekstrom K, Guo X, White WI, Roskos L, Bowen MA, Yang H.

J Proteome Res. 2017 Sep 1;16(9):3124-3136. doi: 10.1021/acs.jproteome.6b01050. Epub 2017 Aug 18.

PMID:
28745510
6.

Activation of Human Peripheral Blood Eosinophils by Cytokines in a Comparative Time-Course Proteomic/Phosphoproteomic Study.

Soman KV, Stafford SJ, Pazdrak K, Wu Z, Luo X, White WI, Wiktorowicz JE, Calhoun WJ, Kurosky A.

J Proteome Res. 2017 Aug 4;16(8):2663-2679. doi: 10.1021/acs.jproteome.6b00367. Epub 2017 Jul 21.

PMID:
28679203
7.

A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.

Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M, Vencovsky J, Rubbert-Roth A, Mysler E, Sleeman MA, Godwood A, Sinibaldi D, Guo X, White WI, Wang B, Wu CY, Ryan PC, Close D, Weinblatt ME; EARTH EXPLORER 1 study investigators.

Ann Rheum Dis. 2017 Jun;76(6):1020-1030. doi: 10.1136/annrheumdis-2016-210624. Epub 2017 Feb 17.

8.

Cytokine-Induced Glucocorticoid Resistance from Eosinophil Activation: Protein Phosphatase 5 Modulation of Glucocorticoid Receptor Phosphorylation and Signaling.

Pazdrak K, Straub C, Maroto R, Stafford S, White WI, Calhoun WJ, Kurosky A.

J Immunol. 2016 Nov 15;197(10):3782-3791. Epub 2016 Oct 14.

9.

Storage Conditions of Conjugated Reagents Can Impact Results of Immunogenicity Assays.

Kubiak RJ, Lee N, Zhu Y, Franch WR, Levitskaya SV, Krishnan SR, Abraham V, Akufongwe PF, Larkin CJ, White WI.

J Immunol Res. 2016;2016:1485615. doi: 10.1155/2016/1485615. Epub 2016 Jul 10.

10.

Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.

Chen D, Ireland SJ, Davis LS, Kong X, Stowe AM, Wang Y, White WI, Herbst R, Monson NL.

J Immunol. 2016 Feb 15;196(4):1541-9. doi: 10.4049/jimmunol.1501376. Epub 2016 Jan 13.

11.

CD4+ T-Cell Profiles and Peripheral Blood Ex-Vivo Responses to T-Cell Directed Stimulation Delineate COPD Phenotypes.

Roberts MEP, Higgs BW, Brohawn P, Pilataxi F, Guo X, Kuziora M, Bowler RP, White WI.

Chronic Obstr Pulm Dis. 2015 Aug 23;2(4):268-280. doi: 10.15326/jcopdf.2.4.2015.0131.

12.

A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity.

Wu Y, Li JJ, Kim HJ, Liu X, Liu W, Akhgar A, Bowen MA, Spitz S, Jiang XR, Roskos LK, White WI.

AAPS J. 2015 Nov;17(6):1417-26. doi: 10.1208/s12248-015-9798-5. Epub 2015 Jul 24.

13.

Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis.

Guo X, Higgs BW, Bay-Jensen AC, Karsdal MA, Yao Y, Roskos LK, White WI.

J Invest Dermatol. 2015 Oct;135(10):2402-2409. doi: 10.1038/jid.2015.188. Epub 2015 May 20.

14.

Recommendations for the evaluation of specimen stability for flow cytometric testing during drug development.

Brown L, Green CL, Jones N, Stewart JJ, Fraser S, Howell K, Xu Y, Hill CG, Wiwi CA, White WI, O'Brien PJ, Litwin V.

J Immunol Methods. 2015 Mar;418:1-8. doi: 10.1016/j.jim.2015.01.008. Epub 2015 Feb 4. Review.

PMID:
25662815
15.

Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis.

Guo X, Higgs BW, Rebelatto M, Zhu W, Greth W, Yao Y, Roskos LK, White WI.

Rheumatology (Oxford). 2014 Apr;53(4):686-95. doi: 10.1093/rheumatology/ket413. Epub 2013 Dec 19.

16.

An electrochemiluminescence (ECL)-based assay for the specific detection of anti-drug antibodies of the IgE isotype.

Wu Y, Liu X, Chen Y, Woods R, Lee N, Yang H, Chowdhury P, Roskos LK, White WI.

J Pharm Biomed Anal. 2013 Dec;86:73-81. doi: 10.1016/j.jpba.2013.06.005. Epub 2013 Jun 28.

PMID:
23988731
17.

Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody.

Wang B, Higgs BW, Chang L, Vainshtein I, Liu Z, Streicher K, Liang M, White WI, Yoo S, Richman L, Jallal B, Roskos L, Yao Y.

Clin Pharmacol Ther. 2013 Jun;93(6):483-92. doi: 10.1038/clpt.2013.35. Epub 2013 Feb 14.

PMID:
23511714
18.

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.

Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, Guo X, Rebelatto M, Le C, Amato A, Fiorentino D, Greenberg SA, Drappa J, Richman L, Greth W, Jallal B, Yao Y.

Ann Rheum Dis. 2014 Jan;73(1):256-62. doi: 10.1136/annrheumdis-2012-202794. Epub 2013 Feb 23.

19.

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.

Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, Neuwelt CM, Robbie G, White WI, Higgs BW, Yao Y, Wang L, Ethgen D, Greth W.

Arthritis Rheum. 2013 Apr;65(4):1011-21. doi: 10.1002/art.37824.

20.

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.

Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, Brohawn P, Kiener PA, Richman L, Fiorentino D, Greenberg SA, Jallal B, Yao Y.

Ann Rheum Dis. 2011 Nov;70(11):2029-36. doi: 10.1136/ard.2011.150326. Epub 2011 Jul 28.

PMID:
21803750
21.

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.

Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B; Lupus Interferon Skin Activity (LISA) Study Investigators.

Ann Rheum Dis. 2011 Nov;70(11):1905-13. doi: 10.1136/ard.2010.144485. Epub 2011 Jul 27.

PMID:
21798883
22.

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma.

Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, Robbie GJ, White WI, White B, Molfino NA; MEDI-528 Clinical Trials Group.

BMC Pulm Med. 2011 Feb 28;11:14. doi: 10.1186/1471-2466-11-14.

23.

A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis.

Bissonnette R, Papp K, Maari C, Yao Y, Robbie G, White WI, Le C, White B.

J Am Acad Dermatol. 2010 Mar;62(3):427-36. doi: 10.1016/j.jaad.2009.05.042.

PMID:
20159310
24.

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.

J Mol Biol. 2007 May 4;368(3):652-65. Epub 2007 Feb 20.

PMID:
17362988
25.

Differential expression of chitinases identify subsets of murine airway epithelial cells in allergic inflammation.

Homer RJ, Zhu Z, Cohn L, Lee CG, White WI, Chen S, Elias JA.

Am J Physiol Lung Cell Mol Physiol. 2006 Sep;291(3):L502-11. Epub 2006 Mar 23.

26.

Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies.

Damschroder MM, Kozhich AA, Woods RM, Cheng L, Mullikin BA, Wilson SD, Ulbrandt ND, Bachy CM, Wu H, Suzich JA, Kiener PA, Dall'Acqua WF, White WI.

Mol Immunol. 2004 Aug;41(10):985-1000.

PMID:
15302161
27.

A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.

Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, O'Brien D, Campbell M, White WI, Balsley J, Reichman RC.

J Infect Dis. 2001 May 15;183(10):1485-93. Epub 2001 Apr 24.

PMID:
11319684
28.

Characterization of a major neutralizing epitope on human papillomavirus type 16 L1.

White WI, Wilson SD, Palmer-Hill FJ, Woods RM, Ghim SJ, Hewitt LA, Goldman DM, Burke SJ, Jenson AB, Koenig S, Suzich JA.

J Virol. 1999 Jun;73(6):4882-9.

29.

Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL.

J Virol. 1998 Jul;72(7):6151-4.

30.

In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16.

White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA.

J Virol. 1998 Feb;72(2):959-64.

31.

Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro.

McCarthy MP, White WI, Palmer-Hill F, Koenig S, Suzich JA.

J Virol. 1998 Jan;72(1):32-41.

32.

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R.

Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11553-7.

33.

Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen.

White WI, Cassatt DR, Madsen J, Burke SJ, Woods RM, Wassef NM, Alving CR, Koenig S.

Vaccine. 1995 Aug;13(12):1111-22.

PMID:
7491819
34.
35.
36.

Benzidine substitute visualizing agents for iron porphyrins.

White WI.

J Chromatogr. 1977 Aug 1;138(1):220-2. No abstract available.

PMID:
893595
37.

Cobalt(III) complexes of bidentate azotyrosine analogs.

White WI, Legg JI.

Bioinorg Chem. 1976;6(2):163-77.

PMID:
1053538
39.
40.

An Anærobic Urinal.

Wats RC, White WI.

Ind Med Gaz. 1931 Dec;66(12):675-676. No abstract available.

41.

The Nature of the Bacterial Substance of an Oral Anti-Dysenteric Vaccine.

Wats RC, White WI.

Ind Med Gaz. 1931 Aug;66(8):435-436. No abstract available.

Supplemental Content

Loading ...
Support Center